Objective:To retrieve, evaluate, and summarize evidence on the nonpharmacological management of chemotherapy-induced peripheral neuropathy (CIPN) to provide an evidence-based basis for the clinical nursing of patients undergoing cancer chemotherapy.Methods:In accordance with the "6S" model of evidence-based search resources, guidelines, evidence summaries, clinical decisions, expert consensus, and systematic reviews on the nonpharmacological management of CIPN were systematically searched on domestic and international websites or databases. The search period was from January 1, 2019 to December 31, 2023.Results:A total of 19 papers were included, including one evidence summary, one guideline, six expert consensus, and 11 systematic reviews. Forty pieces of best evidence in five aspects of assessment/screening, prevention, intervention, clinical management, and health education were summarized.Conclusions:The 40 best evidence for nonpharmacological management of CIPN summarized can be used to prevent or reduce CIPN in cancer patients. Clinical medical and nursing staff should select evidence entries as appropriate for different clinical situations, taking into account the patient's own condition and the feasibility and appropriateness of evidence implementation.

Objective:To retrieve, evaluate, and summarize evidence on the nonpharmacological management of chemotherapy-induced peripheral neuropathy (CIPN) to provide an evidence-based basis for the clinical nursing of patients undergoing cancer chemotherapy.Methods:In accordance with the "6S" model of evidence-based search resources, guidelines, evidence summaries, clinical decisions, expert consensus, and systematic reviews on the nonpharmacological management of CIPN were systematically searched on domestic and international websites or databases. The search period was from January 1, 2019 to December 31, 2023.Results:A total of 19 papers were included, including one evidence summary, one guideline, six expert consensus, and 11 systematic reviews. Forty pieces of best evidence in five aspects of assessment/screening, prevention, intervention, clinical management, and health education were summarized.Conclusions:The 40 best evidence for nonpharmacological management of CIPN summarized can be used to prevent or reduce CIPN in cancer patients. Clinical medical and nursing staff should select evidence entries as appropriate for different clinical situations, taking into account the patient's own condition and the feasibility and appropriateness of evidence implementation.

Objective To construct the bait plasmid of HNP-3 mature peptide in yeast two-hybrid system and examine whether the recombinant bait plasmid has self-activating and toxicity effect.Methods Using RT-PCR technique,the cDNA fragments of HNP-3 mature peptide gene were amplified from the extracted RNA in cultured HL-60 cells.The fragment was firstly cloned into pBluescript-SK-II vector,confirmed by sequencing,then sub-cloned into the bait plasmid pGBKT7 and identified with PCR and sequence analysis techniques.The recombinant plasmid was introduced into the yeast cell AH109,and its self-activating and toxicity effect was tested by auxotrophic selective culture.Results DNA sequencing indicated that the inserted fragment in pBluescript-SK-II vector was HNP-3 mature peptide gene sequence,and the sub-cloned recombinant pGBKT7-HNP-3 was no mismatch.The recombinant bait plasmid didn't have self-activating effect and did not show toxicity to yeast AH109 cell.Conclusion The bait plasmid of HNP-3 mature peptide was constructed successfully.This was helpful for investigating the proteins interacting with HNP-3 mature peptide by yeast two-hybrid technique.

This study sought to clarify the distribution of HMGN2 in HeLa cells. The recombinant eukaryotic expression vectors pcDNA3. 1-myc-his-HMGN2 and pEGFP-N1-HMGN2 were constructed, and then were transfected into HeLa cells. immunocytochemistry staining indicated that HMGN2 were present not only in HeLa nucleus but also in the cytoplasm. The presence of HMGN2 was also detected in the culture supernatant by ELISA with rabbit anti-serum against HMGN2 and mouse anti-His6 monoclonal antibodies. The confocal microscope observation showed the same subcellular localization as that of immunocytochemistry staining. There results suggested that HMGN2 could be present in the nucleus and cytoplasm of HeLa cell as well as in the extracellular environment.
Animals ; Antibodies, Monoclonal ; HMGN2 Protein ; immunology ; metabolism ; pharmacology ; HeLa Cells ; Humans ; Mice ; Rabbits ; Recombinant Fusion Proteins ; biosynthesis ; pharmacology ; Transfection